2024 Alnylam pharmaceuticals inc. - Dr. Pushkal Garg joined Alnylam in 2014 with 15 years of experience in clinical drug development. He oversees all clinical development activities at Alnylam. Prior to joining Alnylam, Dr. Garg served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). He was the strategic leader of the Immunoscience ...

 
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Source: Alnylam Pharmaceuticals, Inc. For Media Inquiries, please contact: Christine Lindenboom. SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340. …. Alnylam pharmaceuticals inc.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline ...Our Science Is Changing the Way Medicine Treats Disease TM. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to ...CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of ...ANALYST COVERAGE. Below is a list of sell-side analysts actively covering Alnylam. Alnylam Pharmaceuticals, Inc., is followed by the analysts listed above. Please note that any opinions, estimates, or forecasts regarding Alnylam Pharmaceuticals, Inc.’s performance made by these analysts are theirs alone and do not represent opinions ...6 Alnylam Clinical Development Pipeline 1 Includes marketing application submissions; 2 Approved in the U.S. and Canada for the PN of hATTR amyloidosis in adults, and in the EU, Japan and other countries for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; 3 Approved in the U.S., Brazil and Canada for the treatmentOur GalNAc-conjugated siRNAs are trivalent, meaning that three GalNAc molecules are clustered and conjugated to one siRNA molecule. This setup guarantees high affinity (strength) of the interaction between ASGPR and the GalNAc ligand, thus promoting optimal efficiency of siRNA delivery to the liver. RNAi therapeutics utilizing GalNAc conjugate ...Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Contacts. Alnylam Pharmaceuticals, Inc.About Alnylam Pharmaceuticals, Inc. Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the ...Alnylam Pharmaceuticals, Inc. Henri A. Termeer Square 675 West Kendall Street Cambridge, MA 02142 USA +1 617-551-8200 alnylam.com Stock Symbol ALNY (Nasdaq) Transfer Agent First Class/Registered/Certified Mail: Computershare Investor Services PO BOX 5050005 Louisville, KY 40233-50005 USA Courier Services Computershare Investor Services6 Alnylam Clinical Development Pipeline 1 Includes marketing application submissions; 2 Approved in the U.S. and Canada for the PN of hATTR amyloidosis in adults, and in the EU, Japan and other countries for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; 3 Approved in the U.S., Brazil and Canada for the treatment of adults with acute hepatic porphyria (AHP ... Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for ... Sep 30, 2023 · Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results. Oct 19, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 19, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial ... Alnylam has over 1,400 full-time employees worldwide as of March 2020. Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for ... CAMBRIDGE, Mass., November 02, 2023 -- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results...Nov 30, 2023 · See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Contacts. Alnylam Pharmaceuticals, Inc.The cases are Alnylam Pharmaceuticals Inc v. Pfizer Inc and Alnylam Pharmaceuticals Inc v. Moderna Inc, U.S. District Court for the District of Delaware, Nos. 1:22-cv-00924 and 1:22-cv-00925.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. Josh Brodsky (Investors) 617-551-8276. Site Navigation. Home. …WebCAMBRIDGE, Mass., July 17, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ...The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Maraganore started his career as a post-doctoral research scientist at Upjohn in Kalamazoo, Michigan, in 1985-86. During 1986-87, he was a senior scientist at Zymogenetics in Seattle, Washington. From 1987 to 1997, he was a senior scientist, group leader of thrombosis and hemostasis research, director of biological research, director of market ...Live Chat Inc. is a tool you can use to interact with customers or clients on the internet. More and more, consumers are demanding and expecting immediate help from the companies they approach. This application enables you to engage with cu...Alnylam Pharmaceuticals also completed a Phase 1 clinical trial (NCT01158079) for ALN-VSP02 in 2012 , which is an LNP with siRNA that targets the expression of vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) . These factors are overexpressed in many tumors and contribute to tumor proliferation …2 Alnylam Pharmaceuticals, Cambridge, MA, USA. [email protected]. 3 Alnylam Pharmaceuticals, Cambridge, MA, USA. [email protected]. # Contributed equally. PMID: 35654979 DOI: 10.1038/s41587-022-01334-x Abstract Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new …Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity. Feb 23, 2023. − Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021 (43% Using Constant Exchange Rate*) –Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Contacts. Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top …WebOct 30, 2023 · NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alnylam Pharmaceuticals, Inc.: On September 13, 2023, Alnylam announced the U.S. Food ... Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam is leading the translation of RNAi (RNA interference) into an innovative new class of medicines to potentially address the needs of patients who ...Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, …Aug 25, 2023 · Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna. Aug 25, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation. Stock analysis for Alnylam Pharmaceuticals Inc (ALNY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.AlCana Technologies, Inc., The University of British Columbia, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Alnylam has elected to extend the companies' RNAi therapeutics research collaboration for a third year.The research collaboration was initiated in August 2009 and …Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes. Sep 13, 2022. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2022-- Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes ...Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines. We’ve been pioneering RNAi therapeutics since 2002 and are excited to share our ongoing scientific progress.The Ionis antisense pipeline. Our antisense technology platform has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 potential first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. The result of 30 years of perfecting and ...Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. J osh Brodsky (Investors) 617-551-8276 Site Navigation. Home. Home; Submit a Press Release;Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. J osh Brodsky (Investors) 617-551-8276 Site Navigation. Home. Home; Submit a Press Release;alnylam pharmaceuticals, inc. annual report on form 10-k for the year ended december 31, 2022 table of contents part i item 1. business 5 item 1a. risk factors 44 item 1b. unresolved staff comments 81 item 2. properties 81 item 3. legal proceedings 82 item 4. mine safety disclosures 82 part ii item 5.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 30, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile-BEE-siran” and formerly known as ALN-AGT), an …Mixed hyperlipidemia is a condition in which high amounts of cholesterol and triglycerides are found in the blood, according to Alnylam Pharmaceuticals. The condition is inherited and can put individuals at higher risk for developing corona...CONTACT US For inquiries or to request additional information, please select the most appropriate phone number or email address from the choices below. Medical Information For medical information, please call: North America 877.ALNYLAM (877.256.9526) Europe +31 20 369 7861 Email: [email protected] 25, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of ... Top 50 Inst. 18,396.10, 82.57, 103,619,357. Institutional Shareholder Style. Style, Holders, Value ($MM), % Inst Shares, Shares ...As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...alnylam pharmaceuticals, inc. annual report on form 10-k for the year ended december 31, 2022 table of contents part i item 1. business 5 item 1a. risk factors 44 item 1b. unresolved staff comments 81 item 2. properties 81 item 3. legal proceedings 82 item 4. mine safety disclosures 82 part ii item 5.Learn what working and interviewing at Alnylam Pharmaceuticals, Inc is really like. Read real reviews, ask and answer questions.Dec 8, 2022 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment ... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 24, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension, which is currently ...Find information about Alnylam's pharmaceutical products: ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and AMVUTTRA® (vutrisiran). 19 Sep, 2022 Ninth Annual RNAi Roundtable Series. Ninth Annual RNAi Roundtable Series. We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as medical thought leaders, will review recent progress in a selection of our pipeline programs and platform innovations, and provide ...19 Sep, 2022 Ninth Annual RNAi Roundtable Series. Ninth Annual RNAi Roundtable Series. We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as medical thought leaders, will review recent progress in a selection of our pipeline programs and platform innovations, and provide ...Dec 15, 2022 · CAMBRIDGE, Mass., December 15, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to ... Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19. Mar 04, 2020 — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential …CAREER OPPORTUNITIES. Today is the day to seize your moment. It’s the day to say Challenge Accepted and make a change that makes a difference for you, your family, and patients. It’s the day to join Alnylam. No matter where you are in your career, if you’re passionate, driven, collaborative, and ready to help change the world, there may ...Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19. Mar 04, 2020 — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential …Sep 30, 2023 · Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results. Oct 19, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 19, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Thursday, November 2, 2023, before the U.S. financial ... The average twelve-month price prediction for Alnylam Pharmaceuticals is $233.00 with a high price target of $395.00 and a low price target of $143.00. Learn more on ALNY's analyst rating history. Do Wall Street analysts like Alnylam Pharmaceuticals more than its competitors? Analysts like Alnylam Pharmaceuticals more than other Medical companies.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. Joshua Brodsky (Investors) 617-551-8276. Site Navigation. Home. Home; Submit a Press Release;hATTR amyloidosis is an inherited, progressive disease caused by a. variant in the TTR gene. This variant causes the TTR protein—which is made primarily in the liver and carries vitamin A—to misfold. The misfolded TTR protein collects as amyloid deposits throughout the body, including the nerves, heart and digestive system.See the latest Alnylam Pharmaceuticals Inc stock price (ALNY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.The cases are Alnylam Pharmaceuticals Inc v. Pfizer Inc and Alnylam Pharmaceuticals Inc v. Moderna Inc, U.S. District Court for the District of Delaware, Nos. 1:22-cv-00924 and 1:22-cv-00925.Latest News Read about our news, announcements, perspectives, media coverage and more. Visit Our Newsroom › Corporate Presentation Get the most updated overview of …WebFeb 23, 2023 · Inside Alnylam Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Expense Highlight. Cost of collaborations and royalties Cost of collaborations and royalties increased during the year ended December 31, 2022, as compared to the year ended December 31, 2021, primarily due to timing and demand of GalNAc material supply to our collaboration partners to support certain product manufacturing ... Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. J osh Brodsky (Investors) 617-551-8276 Site Navigation. Home. Home; Submit a Press Release;Working at Alnylam; Who We Are; Career Opportunities; Search Jobs; Diversity, Equity & Inclusion; Expand Quick Links. Clinical Trials; Corporate Responsibility; Diversity, Equity & Inclusion; Press Releases; Capella (Scientific Presentations) Contact Us2 Alnylam Pharmaceuticals, Cambridge, MA, USA. [email protected]. 3 Alnylam Pharmaceuticals, Cambridge, MA, USA. [email protected]. # Contributed equally. PMID: 35654979 DOI: 10.1038/s41587-022-01334-x Abstract Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new …Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize-winning discovery into an entirely new class of medicines, which we believe has the potential to help people all over the world to live longer, healthier, and fuller lives. Through pioneering science, unwavering commitment to patients, and our approved therapies and ...CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 30, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile-BEE-siran” and formerly known as ALN-AGT), an …Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratoOn September 20, 2022, Alnylam Pharmaceuticals, Inc. announced that the European Commission (EC) had granted marketing authorization for AMVUTTRA® (vutrisiran), an RNAi therapeutics for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.CAMBRIDGE, Mass., October 06, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an ...Download our 2022 Corporate Responsibility Report to review details on Alnylam’s CR policies, practices, and commitments. In all we do, we know we must shift health inequities, addressing the underlying social, environmental, cultural, and economic factors that affect human health – the “social determinants of health,” or SDOH.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Site Navigation. Home. Home; Submit a Press Release;Apr 26, 2023 · Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Regeneron Media Contact: Alexandra Bowie 914-847-3407 [email protected]. Regeneron Investor Contact: Ryan Crowe 914-847-8790 [email protected]. Source: Alnylam Pharmaceuticals, Inc. 2 Alnylam Pharmaceuticals, Cambridge, MA, USA. [email protected]. 3 Alnylam Pharmaceuticals, Cambridge, MA, USA. [email protected]. # Contributed equally. PMID: 35654979 DOI: 10.1038/s41587-022-01334-x Abstract Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new …Dec 15, 2022 · CAMBRIDGE, Mass., December 15, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to ... Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for ... Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity. The Investor Relations website contains information about Alnylam …WebAlnylam Pharmaceuticals. Funding for open access charge: Alnylam Pharmaceuticals. Conflict of interest statement. With the exception of Martin Egli, all authors were employees of Alnylam Pharmaceuticals during the time this work was conducted. REFERENCESAs pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative ...Dec 20, 2021 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 20, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1/2 ... COMMERCIAL & SALES. We aim to be as innovative in commercial execution as we are in drug development. As part of our Commercial and Sales teams, whether you’re interacting with healthcare professionals, payers or patients and their caregivers, you’ll play a critical role in connecting our development efforts to the people we strive to help ...Oct 25, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of ... Alnylam pharmaceuticals inc.

Try using different or fewer filters. If you’re having trouble finding something specific please send an inquiry to [email protected]. Nov 02, 2023. Form 10-Q. Quarterly report which provides a continuing view of a company's financial position. rtf xls pdf. Nov 02, 2023.. Alnylam pharmaceuticals inc.

alnylam pharmaceuticals inc.

Capella—the Online Voice of Progress in RNAi. Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines. We’ve been pioneering RNAi therapeutics since 2002 and are excited to share our ongoing scientific progress.OUR PIPELINE. Alnylam has led the translation of RNAi (RNA interference) into an innovative new class of medicines which silence the genes that cause disease or that contribute to disease. Our pioneering science and pipeline of investigational RNAi therapeutics are focused on addressing the needs of patients who have limited or inadequate ...Dec 21, 2022 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 21, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic ... Pfizer and BioNtech are facing another patent infringement lawsuit related to the vaccines brought by Alnylam Pharmaceuticals Inc in March 2022. Arbutus fell 2.6% to $2.98 on Tuesday, while Pfizer ...Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.WebApr 26, 2023 · Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Regeneron Media Contact: Alexandra Bowie 914-847-3407 [email protected]. Regeneron Investor Contact: Ryan Crowe 914-847-8790 [email protected]. Source: Alnylam Pharmaceuticals, Inc. Mar 31, 2023 · Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity. May 04, 2023. − Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 – T2 Biosystems, Inc. Common Stock. $0.56 +0.1067 +23.54%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ... Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.therapeutics, please visit alnylam.com and engage with us on Twitter at @Alnylam and on LinkedIn. © 2022 Alnylam Pharmaceuticals, Inc. ALNYCFS04/22.Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous ...Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna. Aug 25, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation.Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna. Aug 25, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Regeneron Media Contact: Alexandra Bowie 914-847-3407 [email protected]. Regeneron Investor Contact: Ryan Crowe 914-847-8790Sept 7 (Reuters) - Alnylam Pharmaceuticals (ALNY.O) said on Thursday its experimental gene-silencing therapy helped significantly reduce high blood pressure in patients in a mid-stage trial. The ...Find information about Alnylam's pharmaceutical products: ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and AMVUTTRA® (vutrisiran). Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna. Mar 17, 2022. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 17, 2022-- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) the leading RNAi therapeutics company, announced today that it has separately filed suit in United States District Court for the …Company Agreements. In February 2013, The Medicines Company and Alnylam Pharmaceuticals, Inc., entered into an exclusive global alliance to develop, manufacture and commercialise Alnylam’s ALN-PCS RNAi therapeutics targeting PCSK9 (including inclisiran) for the treatment of hypercholesterolaemia [].Under the terms of …Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Source: Alnylam Pharmaceuticals, Inc. For Media Inquiries, please contact: Christine Lindenboom. SVP, Investor Relations & Corporate Communications [email protected] 617-682-4340. …Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Source: Alnylam Pharmaceuticals, Inc.Alnylam protects its Intellectual Property (IP) with fundamental, chemistry, delivery, and target patents and patent applications covering the design, development and commercialization of RNAi therapeutics as well as that protection afforded by the various trademark, copyright, and trade secret laws. Alnylam’s patent estate includes a large ...Try using different or fewer filters. If you’re having trouble finding something specific please send an inquiry to [email protected]. Nov 02, 2023. Form 10-Q. Quarterly report which provides a continuing view of a company's financial position. rtf xls pdf. Nov 02, 2023.This Master Agreement (this “Agreement”) is made and entered into as of April 8, 2019 (the “Execution Date”) by and between Alnylam Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Alnylam”), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York (“Regeneron”).Alnylam and …RNAi therapeutics is an innovative new class of medicines based on RNA interference (RNAi)—a breakthrough discovery in understanding how genes are regulated naturally within cells. The significance of the discovery of RNAi was recognized with the 2006 Nobel Prize in Medicine or Physiology. Since our founding in 2002, Alnylam has pioneered ...Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1 617-682-4340 Joshua Brodsky (Investors) +1 617-551-8276 Source: Alnylam Pharmaceuticals, Inc. For Media Inquiries, please contact: Christine Lindenboom.RNAi therapeutics is an innovative new class of medicines based on RNA interference (RNAi)—a breakthrough discovery in understanding how genes are regulated naturally within cells. The significance of the discovery of RNAi was recognized with the 2006 Nobel Prize in Medicine or Physiology. Since our founding in 2002, Alnylam has pioneered ...Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic …WebAlnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna. Aug 25, 2023. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an update on its ongoing patent infringement litigation.Capella—the Online Voice of Progress in RNAi. Welcome to Capella, Alnylam’s destination for updates on our work translating the breakthrough discovery of RNA interference (RNAi) into an innovative new class of medicines. We’ve been pioneering RNAi therapeutics since 2002 and are excited to share our ongoing scientific progress.CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 21, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic ...Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Source: Alnylam Pharmaceuticals, Inc.Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Source: …WebAlnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic …WebOUR PIPELINE. Alnylam has led the translation of RNAi (RNA interference) into an innovative new class of medicines which silence the genes that cause disease or that contribute to disease. Our pioneering science and pipeline of investigational RNAi therapeutics are focused on addressing the needs of patients who have limited or inadequate ... Dec 1, 2023 · CI. Morgan Stanley Adjusts Price Target on Alnylam Pharmaceuticals to $183 From $175, Maintains Equal-Weight Rating. Nov. 03. MT. RBC Cuts Price Target on Alnylam Pharmaceuticals to $230 From $235, Keeps Outperform Rating. Nov. 03. MT. Transcript : Alnylam Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023. Alnylam Pharmaceuticals, Inc. («Альнилам Фармасьютикалс, Инк.») - биофармацевтическая компания. Компания занимается изысканием, разработкой и выводом в ...Alnylam Pharmaceuticals, Cambridge, MA Dose-Related and Prolonged Reductions in Blood Pressure with a RNAi Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results from a Phase 1 Study with Zilebesiran (ALN-AGT01) 2Try using different or fewer filters. If you’re having trouble finding something specific please send an inquiry to [email protected]. Nov 02, 2023. Form 10-Q. Quarterly report which provides a continuing view of a company's financial position. rtf xls pdf. Nov 02, 2023.Our GalNAc-conjugated siRNAs are trivalent, meaning that three GalNAc molecules are clustered and conjugated to one siRNA molecule. This setup guarantees high affinity (strength) of the interaction between ASGPR and the GalNAc ligand, thus promoting optimal efficiency of siRNA delivery to the liver. RNAi therapeutics utilizing GalNAc conjugate ...Feb 21, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 21, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in ... Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) ... Alnylam trades on the NASDAQ Stock Market under the symbol ALNY. container. container-970 mb-65 stock-chart .Apple Inc. employs 115,000 employees worldwide, with most being in the U.S. Many other jobs are attributable to Apple, including 627,000 created to support the iOS ecosystem. The company has 478 retail locations worldwide.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Contacts. Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. J osh Brodsky (Investors) 617-551-8276 Site Navigation. Home. Home; Submit a Press Release;Alnylam Pharmaceuticals also completed a Phase 1 clinical trial (NCT01158079) for ALN-VSP02 in 2012 , which is an LNP with siRNA that targets the expression of vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) . These factors are overexpressed in many tumors and contribute to tumor proliferation …ANALYST COVERAGE. Below is a list of sell-side analysts actively covering Alnylam. Alnylam Pharmaceuticals, Inc., is followed by the analysts listed above. Please note that any opinions, estimates, or forecasts regarding Alnylam Pharmaceuticals, Inc.’s performance made by these analysts are theirs alone and do not represent opinions ...Vifor Pharma: Consulting fees Regeneron Pharmaceuticals: Consulting fees Sun Pharma: Consulting fees Verily: Consulting fees Jorg Taubel Alnylam Pharmaceuticals: Investigator Stephen Huanga, Yansong Cheng, Bahru Habtemariam Employees of Alnylam Pharmaceuticals aNow an employee of Beam Therapeutics This study was funded by …alnylam pharmaceuticals, inc. annual report on form 10-k for the year ended december 31, 2022 table of contents part i item 1. business 5 item 1a. risk factors 44 item 1b. unresolved staff comments 81 item 2. properties 81 item 3. legal proceedings 82 item 4. mine safety disclosures 82 part ii item 5. Alnylam P5x25 Commencing in 2022, Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile by 2025.Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative ...Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative ...Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340. J osh Brodsky (Investors) 617-551-8276 Site Navigation. Home. Home; Submit a Press Release;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top …Web. Nasdaq fnko